AOD-9604 beta-3 adrenergic receptor models: reading knockout evidence carefully

Research use only. This article does not provide medical, veterinary, dosing, administration, safety, or outcome guidance.

Mouse models and comparison reported by Heffernan et al.

Heffernan et al. compared AOD-9604, described in the paper as a C-terminal human growth-hormone fragment, with human growth hormone in obese mice and beta(3)-adrenergic-receptor knockout mice. The abstract reports a 14-day chronic experiment and a comparison with wild-type control mice in the knockout analysis.

The reported readouts include body weight, body fat, beta(3)-adrenergic-receptor RNA expression, lipolysis, energy expenditure, and fat oxidation. Each readout belongs to the mouse model and comparison stated by the authors.

Beta(3)-adrenergic-receptor knockout result

For the long-term knockout comparison, the authors report that the body-weight and lipolysis changes observed in wild-type controls were not observed in beta(3)-adrenergic-receptor knockout mice. The authors also report that AOD-9604 increased energy expenditure and fat oxidation in a separate acute knockout experiment. These are reported observations from the named animal models, not properties of a catalogue material.

Author-stated mechanistic limit

The paper concludes that the reported lipolytic actions of human growth hormone and AOD-9604 were not directly mediated through beta(3)-adrenergic receptors, while both compounds increased beta(3)-adrenergic-receptor expression in the study. This conclusion is limited to the materials, models, and measurements in PMID 11713213.

Preserve the knockout comparison

Heffernan et al. report chronic treatment in obese mice and a separate comparison involving beta(3)-adrenergic-receptor knockout mice. The wild-type and knockout animals are not interchangeable groups: genotype, background, diet, treatment duration, and sampling schedule belong in the same citation record. The abstract reports body-weight, body-fat, lipolysis, energy-expenditure, and fat-oxidation readouts, but a short summary should not invent sample sizes, concentrations, or statistical thresholds that are not stated in the cited passage.

Acute and chronic records are different

The paper describes a 14-day chronic experiment and also reports an acute knockout experiment. The author-stated observation that some wild-type changes were not observed in knockout mice is tied to those specific designs. An acute readout cannot be used to fill a missing chronic time point, and a knockout result cannot be generalized to humans, other species, or a different receptor background. Keep the model, comparator, and time course visible whenever the result is quoted.

Second source for terminology

UniProt P01241 provides a reviewed human growth-hormone protein record, useful for distinguishing the human GH term used in the paper from AOD-9604’s description as a lipolytic fragment. This database entry is a terminology aid, not evidence that the mouse test article or the linked AOD-9604 catalogue material has the same sequence, preparation, or lot history. The primary paper remains the source for its own experimental material and endpoints.

What the receptor result does not say

The authors conclude that the reported lipolytic actions were not directly mediated through beta(3)-adrenergic receptors while both compounds increased receptor expression in the study. That conclusion is limited to the named mouse models, treatments, and measurements. It is not a product-performance claim, a mechanism guarantee, or an instruction for use. No catalogue identity, purity, stability, safety, or human or veterinary outcome is established by PMID 11713213.

Research-only boundary: This page explains how to read a knockout-model record. It is not a dosing or administration guide, therapeutic advice, safety assurance, or purchasing recommendation.

Keep model details adjacent to the citation

The paper’s obese-mouse and beta(3)-adrenergic-receptor knockout comparisons have different biological contexts. Record genotype, diet, treatment duration, acute or chronic design, and the measured outcome in the same note. Do not transfer a body-weight or lipolysis observation from one context to another, and do not infer a missing statistical result from a figure label or a later review.

Publication identity check

Europe PMC indexes PMID 11713213 as Heffernan and colleagues’ 2001 Endocrinology article, volume 142, issue 12, pages 5182-5189, DOI 10.1210/endo.142.12.8522. These metadata fields anchor the source and reduce the risk of citing a similarly titled growth-hormone paper. They do not expand the experiment beyond its reported mouse records.

Do not infer a human result

A knockout mouse model can test a mechanistic hypothesis in that model. It cannot establish a human outcome, a veterinary indication, or the performance of a separately supplied AOD-9604 material. State the model and its limits whenever the author conclusion is quoted.

When comparing records, retain the negative control and genotype labels beside each reported readout. A model-dependent result remains model-dependent even when a later catalogue description uses the same peptide name.

Finally, distinguish expression from activation. A reported increase in beta(3)-adrenergic-receptor RNA or protein is a different endpoint from a receptor-mediated lipolytic effect. Keeping those fields separate prevents the author conclusion from being broadened beyond the experiment.

For citation hygiene, keep the 2001 publication date, authors, DOI, and PMID with every quotation. This avoids merging the defined knockout record with later studies that use AOD-9604 terminology but test a different species or endpoint.